Critical Factors Influencing the in Vivo Performance of Long-acting Lipophilic Solutions--impact on in Vitro Release Method Design

Overview

Journal AAPS J

Specialty Pharmacology

Date 2009 Nov 7

PMID 19894123

Citations 18

Authors

Susan Weng Larsen

Claus Larsen

Affiliations

Soon will be listed here.

Abstract

Parenteral long-acting lipophilic solutions have been used for decades and might in the future be used in the design of depots with tailored delivery characteristics. The present review highlights major factors influencing the in vivo performance of lipophilic solutions. Furthermore, an account is given of the characteristics of employed in vitro release methods with a focus on the "state" of sink condition, the stirring conditions, and the oil-water interfacial area. Finally, the capability of in vitro release data to predict the in vivo performance of drug substances administrated in the form of lipophilic solutions is discussed. It is suggested that as long as the major rate-limiting in vivo release mechanism is governed by the drug partitioning between the oil vehicle and the tissue fluid, the use of in vitro release testing in quality control appears to be realistic. With increasing lipophilicity of the drug substances and longer duration of action, the in vivo drug release process may become more complex. As discussed, practical analytical problems together with the inability of release methods to mimic two or more concomitant in vivo events may constitute severe impediments for establishment of in vitro in vivo correlations.

Citing Articles

An Injectable Oil-Based Depot Formulation of -Acyloxymethyl Prodrug of Ropivacaine for Long-Acting Local Analgesia: Formulation Development and In Vitro/In Vivo Evaluation.

Liu X, Zhao R, Xu P, Qian J, Zhang P, Xie X Pharmaceutics. 2025; 17(1).

PMID: 39861687 PMC: 11768344. DOI: 10.3390/pharmaceutics17010037.

Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.

Nakmode D, Singh B, Abdella S, Song Y, Garg S Drug Deliv Transl Res. 2024; 15(4):1156-1180.

PMID: 39661312 PMC: 11870889. DOI: 10.1007/s13346-024-01747-y.

Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective.

Alidori S, Subramanian R, Holm R Mol Pharm. 2024; 21(9):4238-4258.

PMID: 39160132 PMC: 11372838. DOI: 10.1021/acs.molpharmaceut.4c00665.

Tricaprylin-based drug crystalline suspension for intramuscular long-acting delivery of entecavir with alleviated local inflammation.

Jeong M, Ho M, Park J, Jeong H, Kim J, Jang Y Bioeng Transl Med. 2024; 9(4):e10649.

PMID: 39036080 PMC: 11256175. DOI: 10.1002/btm2.10649.

Long-acting intramuscular injections of ELQ-331, an antimalarial agent.

Karunakaran D, Mutyam S, Fu M, Chen J, Pham K, Pou S Eur J Pharm Sci. 2024; 198:106795.

PMID: 38729224 PMC: 11160314. DOI: 10.1016/j.ejps.2024.106795.

References

Larsen S, Ostergaard J, Friberg-Johansen H, Jessen M, Larsen C . In vitro assessment of drug release rates from oil depot formulations intended for intra-articular administration. Eur J Pharm Sci. 2006; 29(5):348-54. DOI: 10.1016/j.ejps.2006.07.002. View

Soderberg L, Dyhre H, Roth B, Bjorkman S . Ultralong peripheral nerve block by lidocaine:prilocaine 1:1 mixture in a lipid depot formulation: comparison of in vitro, in vivo, and effect kinetics. Anesthesiology. 2006; 104(1):110-21. DOI: 10.1097/00000542-200601000-00017. View

Pedersen B, Larsen S, Ostergaard J, Larsen C . In vitro assessment of lidocaine release from aqueous and oil solutions and from preformed and in situ formed aqueous and oil suspensions. Parenteral depots for intra-articular administration. Drug Deliv. 2008; 15(1):23-30. DOI: 10.1080/10717540701828657. View

Larsen S, Rinvar E, Svendsen O, Lykkesfeldt J, Friis G, Larsen C . Determination of the disappearance rate of iodine-125 labelled oils from the injection site after intramuscular and subcutaneous administration to pigs. Int J Pharm. 2001; 230(1-2):67-75. DOI: 10.1016/s0378-5173(01)00860-2. View

Wistuba J, Luetjens C, Kamischke A, Gu Y, Schlatt S, Simoni M . Pharmacokinetics and pharmacodynamics of injectable testosterone undecanoate in castrated cynomolgus monkeys (Macaca fascicularis) are independent of different oil vehicles. J Med Primatol. 2005; 34(4):178-87. DOI: 10.1111/j.1600-0684.2005.00115.x. View

Martinez M, Rathbone M, Burgess D, Huynh M . In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting. J Control Release. 2008; 129(2):79-87. DOI: 10.1016/j.jconrel.2008.04.004. View

DSouza S, DeLuca P . Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech. 2005; 6(2):E323-8. PMC: 2750545. DOI: 10.1208/pt060242. View

Chien Y . Long-acting parenteral drug formulations. J Parenter Sci Technol. 1981; 35(3):106-39. View

Wicks S, Kaye B, Weatherley A, Lewis D, Davison E, Gibson S . Effect of formulation on the pharmacokinetics and efficacy of doramectin. Vet Parasitol. 1993; 49(1):17-26. DOI: 10.1016/0304-4017(93)90219-d. View

10.

Janicki S, Sznitowska M, Zebrowska W, Gabiga H, Kupiec M . Evaluation of paracetamol suppositories by a pharmacopoeial dissolution test--comments on methodology. Eur J Pharm Biopharm. 2001; 52(2):249-54. DOI: 10.1016/s0939-6411(01)00187-4. View

11.

Matsunaga Y, Nambu K, Miyazaki H, Hashimoto M . Absorption of intramuscularly administered [14C]haloperidol decanoate in rats. Eur J Drug Metab Pharmacokinet. 1987; 12(3):175-81. DOI: 10.1007/BF03189894. View

12.

Soderberg L, Dyhre H, Roth B, Bjorkman S . The "inverted cup" -- a novel in vitro release technique for drugs in lipid formulations. J Control Release. 2006; 113(1):80-8. DOI: 10.1016/j.jconrel.2006.03.015. View

13.

. Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatry. 1989; 13(1-2):77-85. DOI: 10.1016/0278-5846(89)90005-5. View

14.

Medlicott N, Waldron N, Foster T . Sustained release veterinary parenteral products. Adv Drug Deliv Rev. 2004; 56(10):1345-65. DOI: 10.1016/j.addr.2004.02.005. View

15.

Behre H, Abshagen K, Oettel M, Hubler D, Nieschlag E . Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol. 1999; 140(5):414-9. DOI: 10.1530/eje.0.1400414. View

16.

Belkien L, Schurmeyer T, Hano R, Gunnarsson P, Nieschlag E . Pharmacokinetics of 19-nortestosterone esters in normal men. J Steroid Biochem. 1985; 22(5):623-9. DOI: 10.1016/0022-4731(85)90215-8. View

17.

Scriba G, Lambert D, Poupaert J . Bioavailability of phenytoin following oral administration of phenytoin-lipid conjugates to rats. J Pharm Pharmacol. 1995; 47(11):945-8. DOI: 10.1111/j.2042-7158.1995.tb03275.x. View

18.

Larsen C, Ostergaard J, Larsen S, Jensen H, Jacobsen S, Lindegaard C . Intra-articular depot formulation principles: role in the management of postoperative pain and arthritic disorders. J Pharm Sci. 2008; 97(11):4622-54. DOI: 10.1002/jps.21346. View

19.

LARSEN D, Fredholt K, Larsen C . Assessment of rate of drug release from oil vehicle using a rotating dialysis cell. Eur J Pharm Sci. 2000; 11(3):223-9. DOI: 10.1016/s0928-0987(00)00105-6. View

20.

Liu K, Tzeng J, Chen Y, Huang K, Kuei C, Wang J . Novel depots of buprenorphine prodrugs have a long-acting antinociceptive effect. Anesth Analg. 2006; 102(5):1445-51. DOI: 10.1213/01.ane.0000205747.05693.30. View